GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » Financial Strength

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Financial Strength : 10 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co Financial Strength?

Anhui Wanbang Pharmaceutical Technology Co has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Anhui Wanbang Pharmaceutical Technology Co Ltd shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Anhui Wanbang Pharmaceutical Technology Co has no long-term debt (1). Anhui Wanbang Pharmaceutical Technology Co's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.00. As of today, Anhui Wanbang Pharmaceutical Technology Co's Altman Z-Score is 26.85.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.


Competitive Comparison of Anhui Wanbang Pharmaceutical Technology Co's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Anhui Wanbang Pharmaceutical Technology Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anhui Wanbang Pharmaceutical Technology Co's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anhui Wanbang Pharmaceutical Technology Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Anhui Wanbang Pharmaceutical Technology Co's Financial Strength falls into.



Anhui Wanbang Pharmaceutical Technology Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Anhui Wanbang Pharmaceutical Technology Co's Interest Expense for the months ended in Mar. 2024 was ¥0.0 Mil. Its Operating Income for the months ended in Mar. 2024 was ¥23.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0.0 Mil.

Anhui Wanbang Pharmaceutical Technology Co's Interest Coverage for the quarter that ended in Mar. 2024 is

Anhui Wanbang Pharmaceutical Technology Co had no long-term debt (1).

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Anhui Wanbang Pharmaceutical Technology Co Ltd has no debt.

2. Debt to revenue ratio. The lower, the better.

Anhui Wanbang Pharmaceutical Technology Co's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 360.688
=0.00

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Anhui Wanbang Pharmaceutical Technology Co has a Z-score of 26.85, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 26.85 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anhui Wanbang Pharmaceutical Technology Co  (SZSE:301520) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Anhui Wanbang Pharmaceutical Technology Co has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.


Anhui Wanbang Pharmaceutical Technology Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Traded in Other Exchanges
N/A
Address
southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000
Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines